The Food and Drug Administration (FDA) is advising consumers to not buy or use Sit and Slim II, a product promoted and sold for weight loss.

An FDA analysis confirmed that Sit and Slim II contains sibutramine, a controlled substance that was removed from the market in October 2010 due to safety concerns. Sibutramine is known to substantially increase blood pressure and/or pulse rate in some patients and may pose a significant risk in patients with a history of coronary artery disease, congestive heart failure, arrhythmias, or stroke.

RELATED: Temperature Excursions Lead to Vancomycin Injection Recall

The FDA analysis also confirmed that Sit and Slim II contains phenolphthalein, a chemical not present as an active ingredient in the U.S. Studies have shown that it presents a cancer-causing risk.

Sit and Slim II is sold on various websites and in some retail stores.

For more information call (800) 332-1088 or visit FDA.gov.